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Objective: To develop evidence-based recommendations for the management of systemic glucocorticoid (GC)
therapy in rheumatic diseases.
Methods: The multidisciplinary guideline development group from 11 European countries, Canada and the
USA consisted of 15 rheumatologists, 1 internist, 1 rheumatologist–epidemiologist, 1 health professional, 1
patient and 1 research fellow. The Delphi method was used to agree on 10 key propositions related to the
safe use of GCs. A systematic literature search of PUBMED, EMBASE, CINAHL, and Cochrane Library was
then used to identify the best available research evidence to support each of the 10 propositions. The strength
of recommendation was given according to research evidence, clinical expertise and perceived patient
preference.
Results: The 10 propositions were generated through three Delphi rounds and included patient education, risk
factors, adverse effects, concomitant therapy (ie, non-steroidal anti-inflammatory drugs, gastroprotection and
cyclo-oxygenase-2 selective inhibitors, calcium and vitamin D, bisphosphonates) and special safety advice
(ie, adrenal insufficiency, pregnancy, growth impairment).
Conclusion: Ten key recommendations for the management of systemic GC-therapy were formulated using a
combination of systematically retrieved research evidence and expert consensus. There are areas of
importance that have little evidence (ie, dosing and tapering strategies, timing, risk factors and monitoring for
adverse effects, perioperative GC-replacement) and need further research; therefore also a research agenda
was composed.
S
ince 1948, glucocorticoids (GCs) have been widely used in
medicine.1 Although GCs soon became associated with the
occurrence of adverse effects (AEs), they are still the most
frequently used anti-inflammatory and immune-suppressive
drugs in rheumatic diseases. Recent studies have demonstrated
the disease-modifying potential of low-dose GCs in rheumatoid
arthritis (RA) and this has renewed the debate on the risk–
benefit ratio of this treatment.2 Current literature on the risk–
benefit ratio of GCs is nevertheless inconsistent, and inap-
propriate use of GCs could lead to increased toxicity;3 this
emphasises the need for clear statements on proper use of GCs.
Hence, a EULAR task force on GCs, including a patient, was
formed to develop evidence-based recommendations, to provide
a tool for the better use and management of GC-therapy in
rheumatic diseases.
METHODS
Endorsed by EULAR-ESCISIT, a multidisciplinary guideline
development committee on GCs was formed, consisting of 20
experts in the field of GCs from 11 European countries, Canada
and the USA: 15 rheumatologists, 1 internist, 1 rheumatolo-
gist–epidemiologist, 1 health professional, 1 patient and 1
research fellow. The Delphi method was used to agree on 10 key
propositions related to the risk–benefit ratio of GCs, and
EULAR standardised operating procedures4 were then followed:
(1) to identify and critically appraise research evidence for the
10 propositions, performing a systematic literature search of
PUBMED, EMBASE, CINAHL and Cochrane Library; (2) to
generate and validate recommendations based on the best
available evidence, according to research, clinical expertise and
perceived patient preference (levels of evidence are defined in
table 1); and (3) to formulate a future research agenda.
RESULTS
First, a general literature search was performed (appendix 1 of the
full version of the article; available web-only at http://www.annr-
heumdis.com/supplemental), including the estimated incidence
of different types of AEs as derived from studies reporting on
frequencies of AEs of GCs (see fig 1 and table 2). Second, after the
taskforce experts had discussed the results of this general
literature search, the Delphi exercise was initiated. At the start,
153 (partly overlapping) propositions were produced, and after 2
anonymous Delphi rounds 10 final propositions were agreed upon
(table 3). Third, proposition-specific searches were done, resulting
in 5089 potentially useful studies, of which 165 were included to
provide (circumstantial) evidence for propositions (table 4).
Recommendations
1. The adverse effects of glucocorticoid therapy should be
considered and discussed with the patient before glucocorticoid
therapy is started. This advice should be reinforced by giving
information regarding glucocorticoid management. If gluco-
corticoids are to be used for a more prolonged period of time, a
‘‘glucocorticoid card’’ is to be issued to every patient, with the
Abbreviations: AE, adverse effect; BMD, bone-mineral density; DMARD,
disease-modifying antirheumatic drug; GC, glucocorticoid; GCA, giant cell
arthritis; GHR, growth-hormone replacement; NSAID, non-steroidal anti-
inflammatory drug; PMR, polymyalgia rheumatica; PPI, proton pump
inhibitor; RA, rheumatoid arthritis
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date of commencement of treatment, the initial dosage and the
subsequent reductions and maintenance regimens.
N Level of evidence: IV
N Strength of recommendation (95% CI):
– Overall: 91 (86 to 96)
– Pretreatment advice: 92 (85 to 100)
– Information: 88 (80 to 96)
– Glucocorticoid card: 78 (67 to 89)
We recommend that the frequency of AEs during GC-therapy
(table 2) should be categorised following WHO guidelines: very
common (.1/10 patients); common (.1/100); uncommon
(.1/1000); rare (.1/10 000); very rare (,1/100 000).5
Detailed discussion of common and very common AEs of
therapy is an integral part of the management of any disease
and of patient education. Because patients’ perspectives on AEs
might differ from doctors’ perspectives, patient information
should include both perspectives (category IV evidence). In a
population-based cohort, 68% of patients who used GCs
recalled discussing potential GC-related AEs with their practi-
tioner.6 This recall might be influenced by the perception of
severity of GC-related AEs, which may differ among patients.7
Whether discussion of possible AEs before GC-therapy has
any beneficial effect on disease outcome—for example by
improving patient compliance—is unclear because of lacking
data. However, general patient education, including discussing
possible AEs of other treatment, positively influences outcome
of therapy.8–11 In contrast, in a controlled clinical study the
knowledge about AEs of beta-blockers produced anxiety.12 So,
in giving information, individual patient psychological char-
acteristics should be taken into account. The format of patient
education—for example the use of information leaflets—has
not been investigated in long-term GC-therapy, so this part of
the recommendation is also supported by expert opinion only.
Likewise, no evidence was found to support the use of
‘‘glucocorticoid cards’’, but the use of a pocket card in
methotrexate (MTX) users improved patients’ knowledge on
safety and toxicity of MTX.9
2. Initial dose, dose reduction and long-term dosing depend
on the underlying rheumatic disease, disease activity, risk
factors and individual responsiveness of the patient. Timing
may be important, with respect to the circadian rhythm of both
the disease and the natural secretion of glucocorticoids.
N Level of evidence: I–III
N Strength of recommendation (95% CI):
– Overall: 83 (70 to 97)
– Dose regimens: 92 (83 to 100)
– Dose timing: 74 (59 to 89)
Table 1 Levels of evidence
I-A Meta-analysis of randomised controlled trials
I-B Randomised controlled trial
II-A Controlled study without randomisation
II-B Quasi-experimental study
III Descriptive studies (comparative, correlation, case-control)
IV Expert committee reports/opinions and/or clinical opinion of respected authorities
Figure 1 Different study populations of the included studies from the
general search.
Table 2 Reported AEs in GC-treated patients with rheumatic diseases: results of the general search
Type of AE
Median: (25th to 75th percentiles)
(AEs per 100 patient years)
Cardiovascular (dyslipidemia, water and electrolyte imbalance, oedema, renal and heart dysfunction, hypertension) 15 (3 to 28)
Infectious (viral, bacterial, skin infections) 15 (3 to 15)
Gastro-intestinal (peptic ulcer disease, pancreatitis) 10 (4 to 20)
Psychological and behavioural (minor mood disturbances, steroid psychosis) 9 (2 to 236)
Endocrine and metabolic (glucose intolerance and diabetes, fat redistribution, interference with hormone secretion) 7 (3 to 34)
Dermatological (cutaneous atrophy, acne, hirsutism, alopecia) 5 (2 to 80)
Musculoskeletal (osteoporosis, osteonecrosis, myopathy) 4 (3 to 9)
Ophtalmological (glaucoma, cataract) 4 (0 to 5)
This table summarises reported AEs in studies (n = 18) of the general search of patients using GCs (n = 963) for a rheumatic disease. Only those studies of patients who
were using GCs up to 30 mg prednisolone or equivalent and reporting dichotomous AE outcomes were included in the data of the table, which was used as introductory
information for the taskforce. Raw data, not corrected for disease activity, co-morbidity and the frequency of AEs in the contrast group, if present, were used. So, not all
AEs can be specifically attributed to the use of GCs; common events may be overestimated and less common ones underestimated. For instance, cardiovascular events
are poorly correlated with GC-use. Types of AEs were divided into different groups (as has been published before25) and per group AEs per 100 patient years were
derived by dividing the number of AEs by the duration of follow-up in years, times 100. The mean daily GC-dose was 8 mg, and the average duration of the studies was
19.6 months.
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Dosing strategies were assessed in one retrospective and
three prospective studies on short- to intermediate-term GC
treatment in polymyalgia rheumatica (PMR) and giant cell
arthritis (GCA) patients needing low initial dosages had fewer
relapses and lower maintenance dose, and experienced less
toxicity (category III).13–16 In early RA (disease duration ,2
years), the use of low-dose GCs is based not solely on disease
symptoms, but also on joint sparing effects on the long-term, as
GCs can be categorised as disease-modifying antirheumatic
drugs (DMARDs) (category IA).2 Different regimens with GCs
have been used for joint sparing purposes in early RA, usually
in combination with other DMARDs. These different schemes
could result in different disease outcomes, but data are lacking.
A relation between dose strategies and risk factors, such as
diabetes, hypertension and osteoporosis, can only be shown
indirectly (category IIB–III).17–20 It is unknown whether an
individual response on the same GC-dose is different among
individuals, since no study was found on the relation between
dose strategies and individual responsiveness of patients.
The timing of GC-administration might influence its efficacy,
as both signs and symptoms (such as morning stiffness) of RA21
as well as serum levels of several pro-inflammatory cytokines22
Table 3 Experts’ propositions developed throughout 3 Delphi rounds including the strength of recommendation
Proposition
SOR
Evidence
level of dataVAS 100 (95% CI) A+B %
1 a The adverse effects of glucocorticoid therapy should be considered and discussed with the patient before
glucocorticoid therapy is started
92 (85 to 100) 93 IV
1 b This advice should be reinforced by giving information regarding glucocorticoid management 88 (80 to 96) 93 IV
1 c If glucocorticoids are to be used for a more prolonged period of time, a ‘‘glucocorticoid card’’ is to be
issued to every patient, with the date of commencement of treatment, the initial dosage and the
subsequent reductions and maintenance regimens
78 (67 to 89) 79 IV
1 Full proposition (1A+1B+1C) 91 (86 to 96) 92
2 a Initial dose, dose reduction and long-term dosing depend on the underlying rheumatic disease,
disease activity, risk factors and individual responsiveness of the patient
92 (83 to 100) 86 IA–III
2 b Timing may be important, with respect to the circadian rhythm of both the disease and the natural
secretion of glucocorticoids
74 (59 to 89) 57 –
2 Full proposition (2A+2B) 83 (70 to 97) 85
3 When it is decided to start glucocorticoid treatment, comorbidities and risk factors for adverse effects
should be evaluated and treated where indicated; these include hypertension, diabetes, peptic ulcer,
recent fractures, presence of cataract or glaucoma, presence of (chronic) infections, dyslipidaemia and
comedication with non-steroidal anti-inflammatory drugs
92 (87 to 96) 100 IV
4 For prolonged treatment, the glucocorticoid dosage should be kept to a minimum, and a glucocorticoid
taper should be attempted in case of remission or low disease activity; the reasons to continue
glucocorticoid therapy should be regularly checked
81 (68 to 94) 86 IV
5 During treatment, patients should be monitored for body weight, blood pressure, peripheral oedema,
cardiac insufficiency, serum lipids, blood and/or urine glucose and ocular pressure depending on
individual patient’s risk, glucocorticoid dose and duration
89 (81 to 97) 93 IV
6a If a patient is started on prednisone >7.5 mg daily and continues on prednisone for more than 3 months,
calcium and vitamin D supplementation should be prescribed
95 (91 to 99) 100 IA
6b Antiresorptive therapy with bisphosphonates to reduce the risk of glucocorticoid-induced osteoporosis
should be based on risk factors, including bone-mineral density measurement
96 (92 to 99) 93 IB–III
6 Full proposition (6A+6B) 95 (89 to 100) 100
7 Patients treated with glucocorticoids and concomitant non-steroidal anti-inflammatory drugs should be
given appropriate gastro-protective medication, such as proton pump inhibitors or misoprostol, or
alternatively could switch to a cyclo-oxygenase-2 selective inhibitor
91 (84 to 98) 93 1A–IB
8 All patients on glucocorticoid therapy for longer than 1 month, who will undergo surgery, need
perioperative management with adequate glucocorticoid replacement to overcome potential adrenal
insufficiency
91 (84 to 99) 93 IV
9 Glucocorticoids during pregnancy have no additional risk for mother and child 87 (78 to 96) 86 IB–III
10 Children receiving glucocorticoids should be checked regularly for linear growth and considered for
growth-hormone replacement in case of growth impairment
93 (85 to 100) 93 IB
*A+B%, percentage of the taskforce members that strongly to fully recommended this proposition, based on an A–E ordinal scale; CI, confidence interval; SOR, strength
of recommendation; VAS, visual analogue scale (0–100 mm, 0 = not recommended at all, 100 = fully recommended).
Table 4 Evidence delivered by the proposition-specific searches
Proposition Proposition-specific search, n studies No. of studies meeting inclusion criteria Type of evidence*
1 2699 34 Circumstantial
2 556 16 Partially direct
3 464 29 Circumstantial
4 131 4 Circumstantial
5 401 4 Circumstantial
6 71 19 Indirect
7 157 15 Indirect
8 303 13 Circumstantial
9 86 19 Partially indirect and partially direct
10 221 19 Indirect
Total 5089 172 (165 minus duplicates)
*Indirect: data directly support the proposition. Circumstantial: no data directly or indirectly support the proposition, but there are circumstantial data which are useful to
the proposition. Partially direct: part of the proposition is directly supported by data.
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show a circadian rhythm with a flare at the beginning of the
day. Administration of GCs early in the morning23 (category
IB), or the use of modified release tablet of prednisone,
delivering the GC early in the morning (abstract)24 gave more
improvement of RA symptoms than conventional timing of GC-
therapy.
In conclusion, there is category III evidence on dosing
regimens of GCs in PMR/GCA and category IA evidence
showing a benefit for the use of low-dose long-term GCs in
early RA. The relation between risk factors, AEs, high GC-
dosages and long-term GC-use was indirectly shown for
diabetes (category IIB) and hypertension (category III). No
study was identified on individual responsiveness to GC
(category IV). There are category IB data on a superior effect
of circadian administration of GCs.
3. When it is decided to start glucocorticoid treatment,
comorbidities and risk factors for adverse effects should be
evaluated and treated where indicated. These include hyperten-
sion, diabetes, peptic ulcer, recent fractures, presence of cataract or
glaucoma, presence of (chronic) infections, dyslipidemia and co-
medication with non-steroidal anti-inflammatory drugs.
N Level of evidence: IV
N Strength of recommendation (95% CI): 92 (87 to 96)
Even though the above-mentioned risk factors for GC-
associated AEs are well known,25 and there is obvious face
validity trying to prevent these from occurring by assessing and
treating comorbidities and risk factors at baseline, there is no
evidence to show that this is effective (category IV).
4. For prolonged treatment, the glucocorticoid dosage should
be kept to a minimum, and a glucocorticoid taper should be
attempted in case of remission or low disease activity. The
reasons to continue glucocorticoid therapy should be checked
regularly.
N Level of evidence: IV
N Strength of recommendation (95% CI): 81 (68 to 94)
This proposition is supported by expert opinion alone,
although this proposition has obvious face validity, since the
occurrence of GC-related AEs, osteoporosis in particular
(proposition 5 and 6), is dependent on dose and duration of
therapy.
5. During treatment, patients should be monitored for body
weight, blood pressure, peripheral oedema, cardiac insuffi-
ciency, serum lipids, blood and/or urine glucose and ocular
pressure depending on individual patient’s risk, glucocorticoid
dose and duration.
N Level of evidence: IV
N Strength of recommendation (95% CI): 89 (81 to 97)
There is no direct evidence from appropriately designed
studies to support this proposition (category IV). Since risks of
AEs during GC-treatment are related to GC-dose and duration
of treatment, monitoring should be dependent on both
Table 5 Theoretical framework of criteria which can be used to decide whether monitoring for specific AEs is useful
No. needed to screen?
(1/prevalence per year)
Severity?
(Low/moderate/high)
Cost of screening?
(Low/moderate/high)
Feasibility of scoring?
(Low/moderate/high)
Body weight 1.5 6 Low Low High
Blood pressure ? Moderate Low High
Peripheral oedema ? Low Low High
Heart failure ? High Moderate Moderate*
Dyslipidemia ? Moderate Moderate Moderate*
Blood/urine glucose 12.5 6 Moderate Moderate High
Glaucoma 18.1 84 Moderate Moderate Moderate*
*Scoring in daily practice depends on presence of accurate laboratory tests and/or eye-pressure measurement equipment.
Figure 2 Example of an algorithm for osteoporosis prevention in glucocorticoid users.
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variables. Furthermore, monitoring for an AE is especially useful if
the AE is preventable or treatable, common, severe, and if the cost
of screening is low and monitoring is feasible in daily clinical
practice. Also, non-modifiable AEs should be assessed, as they
could be important from the patient’s perspective and could be a
surrogate marker for other AEs (eg, reflecting patient’s sensitivity
to GCs), alerting the physician. A theoretical framework showing
elements of the discussion on monitoring the above-mentioned
AEs is found in table 5, based upon group consensus after
discussing all propositions.
6. If a patient is started on prednisone >7.5 mg daily and
continues on prednisone for more than 3 months, calcium and
vitamin D supplementation should be prescribed.
Antiresorptive therapy with bisphosphonates to reduce the risk
of glucocorticoid-induced osteoporosis should be based on risk
factors, including bone-mineral density (BMD) measurement.
N Level of evidence: I
N Strength of recommendation (95% CI):
– Overall: 95 (89 to 100)
– Calcium and vitamin D: 95 (91 to 99)
– Bisphosphonates: 96 (92 to 99)
Calcium and vitamin D supplementation have been shown to
reduce GC-induced bone loss and fractures (category IA).26 27
However, they do not totally prevent GC-induced bone loss, in
contrast to bisphosphonates, which have been proven superior
in this respect (category IA).28 Bisphosphonate therapy can be
indicated, based on the following risk factors: decreased BMD,
female gender, older age, postmenopausal status and low body
mass index (category IIB).29 Both GC-dose and low BMD have
been shown to be predictors of fractures, but at the same BMD
level, postmenopausal patients on GCs were more prone to
getting fractures than postmenopausal patients without this
therapy (category 1B).30 The ACR has published a clear
guideline on the treatment of GC-induced osteoporosis,31 and
several algorithms have been proposed to decide whether or not
to start with bisphosphonates based on GC-dosage, pre-existent
fractures, age and gender, menopause, and BMD measure-
ment32 33 (fig 2 gives an example).
7. Patients treated with glucocorticoids and concomitant
non-steroidal anti-inflammatory drugs (NSAIDs) should be
given appropriate gastro-protective medication, such as proton
pump inhibitors (PPIs) or misoprostol, or alternatively could
switch to a cyclo-oxygenase-2 selective inhibitor (coxib).
N Level of evidence: I
N Strength of recommendation (95% CI): 91 (84 to 98)
No study investigated gastro-protective measures in GC-
using patients specifically, but the rationale for this proposition
is given by the fact that gastro-intestinal (GI) toxicity possibly
increases by treatment with GCs alone (see proposition 3).
Likewise, although not studied in GC-using patients specifi-
cally, several treatment regimens have been shown to be gastro-
protective for conventional NSAID users. Proton pump inhibi-
tors (PPIs) and misoprostol reduce the risk of gastric and
duodenal ulcers in patients taking conventional NSAIDs
(category I B),34 35 and cyclo-oxygenase-2 inhibitors cause less
GI toxicity than conventional NSAIDs in RA patients (category I
B).36–38 However, conventional NSAIDs combined with PPI
cause less dyspepsia than cyclo-oxygenase-2 inhibitors do
(category I A).39 In deciding on the prescription of cyclo-
oxygenase-2 inhibitors and conventional NSAIDs, cardiovascu-
lar risk factors should also be taken into account.40–45
8. All patients on glucocorticoid therapy for longer than
1 month, who will undergo surgery, need perioperative
management with adequate glucocorticoid replacement to
overcome potential adrenal insufficiency.
N Level of evidence: IV
N Strength of recommendation (95% CI): 91 (84–99)
Adrenal insufficiency due to surgical stress has already been
described in the 1950s.46 As patients with RA and PMR are
considered to have relative adrenal insufficiency due to their
disease,47 they might be more prone to adrenal insufficiency at
surgery. The incidence and duration of GC-induced adrenal
insufficiency depend, apart from possible individual differences
in sensitivity for GC, on the type and dosage of GC48 49 and the
duration of therapy. GC-treatment of less than 3 weeks or
alternate-day therapy does not exclude the risk of suppression
of the hypothalamic–pituitary–adrenal axis,50 51 but the risk is
still dose-dependent.52
GC-replacement is recommended in case of surgery for
patients at risk of adrenal insufficiency (category IV). For
moderate physical stress-inducing procedures, a single dose of
100 mg of hydrocortisone intravenously has been proposed, and
for major surgery, 100 mg of hydrocortisone intravenously
before anaesthesia and every 8 h 4 times thereafter.53 The dose
can be gradually tapered by half per day afterwards. However,
several other schemes of GC-replacement exist.
9. Glucocorticoids during pregnancy have no additional risk
for mother and child.
N Level of evidence:
– Mother: IV
– Child: I–III
N Strength of recommendation (95% CI): 87 (78 to 96)
Safety of GC-usage during pregnancy refers to both the mother
and the unborn child. First, for the pregnant mother, the spectrum
of AEs associated with the use of GCs is believed not to differ
between a pregnant patient and a non-pregnant patient (category
IV evidence), but since pregnant or lactating women are more at
risk for pregnancy-associated Aes, which are also seen as AE of
GC-therapy (eg, osteoporosis,54 diabetes,55 hypertension56), this
risk of these AEs could be especially increased by GC-therapy for
these women, but no data are available.
Second, regarding the safety of GCs for the fetus and
neonate, dexamethasone can be used to treat fetal conditions
such as immature lungs, because it is not metabolised well by
the placenta, and so higher dosages are available to the fetus.
Prednisone, prednisolone and methylprednisolone are less
available to the fetus (10% of the maternal dose), and so these
substances are preferred for the treatment of maternal
disorders.57 GCs prior to and during pregnancy do not seem to
have a negative impact on the development of the fetus. GCs in
high doses have caused low birth weights in humans and cleft
palate in experimental animal models,58 59 but there is no
evidence that in humans prednisone or methylprednisolone are
teratogenic (Food and Drug Administration risk category B,60),
category III evidence.61 The incidence of infection was not
increased in neonates who had been exposed to GCs in utero
(category IB).62
GCs are excreted minimally into breast milk,63 64 and
breastfeeding by women on low-dose GC-therapy is generally
considered to be safe.65 Exposure of an infant can be further
minimised if breastfeeding is avoided during the first 4 h after
GC-intake, because there is an equilibrium between the
concentration of prednisolone in mother milk and serum.64
10. Children receiving glucocorticoids should be checked
regularly for linear growth and considered for growth-hormone
replacement in case of growth impairment.
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N Level of evidence: I
N Strength of recommendation (95% CI): 93 (85 to 100)
GCs can cause growth retardation in children (category I
B).66–69 The pathogenesis of this growth impairment is multi-
faceted. Growth-hormone replacement (GHR) can be used to
prevent growth impairment due to GCs: an increase in linear
growth with GHR was shown in several studies of GC-using JIA
patients (category I–III),70–75 and in studies of ‘‘slowly growing
GC-treated patients’’ (category II).76 77 The daily GC-doses used
in these studies varied between 0.2 and 0.5 mg/kg prednisolone
equivalent, and the duration GHR therapy was 2–4 years.
If GHR is considered, referral to an experienced paediatrician
is indicated (category IV evidence), and additional testing can
confirm growth-hormone deficiency. Routine usage of GHR in
GC-using patients is hampered by several factors: the therapy
involves daily injections (subcutaneously or intramuscularly),
the length gain is relatively small, and it is a very costly therapy
(between J15 000 and J50 000 annually, depending on the
weight of the individual child78).
DISCUSSION
This EULAR document on the safer use of systemic GCs in
rheumatic diseases used a similar design to that of earlier
EULAR taskforces,79–82 i.e. a combination of both evidence and
expert opinion. The added value of this taskforce, like previous
ones, is provided by the fact that they (1) are a broad
representation of experts in the field of GCs within and outside
Europe; (2) use recent research data; and (3) use a thorough
evidence-based format. The order of 10 propositions in the
paper does not reflect importance, but more or less the logical
order of patient management. Both the level of evidence of each
proposition and the strength of recommendations are given.
This approach has led to a reduction of personal bias, good
external validity and generalisability, and clear identification of
areas of clinical practice where more research data are
required.83 The propositions promote the safer use of GCs
among physicians and patients alike in daily clinical practice,
and they will form the basis of further EULAR research and
education.
These recommendations have some limitations. Since GCs
are used quite extensively, the search results were often
overwhelming. To overcome this, we used more specific search
strategies in which relevant studies might have been over-
looked. Second, the selection of circumstantial evidence in the
absence of direct evidence has some degree of subjectivity.
Third, in the literature, the evidence hierarchy has focused on
treatment efficacy, whereas evidence on safety might be better
graded by other study types than RCTs. Other grading systems
might be preferred for grading future studies on safety.
The literature search showed that studies on GCs in general
lack a systemic assessment of AEs and that AEs often are poorly
described, let alone defined, which made it difficult to provide
direct evidence for most propositions. It is therefore advisable to
monitor a well-defined list of AEs in a standardised manner in
future studies, taking into account patients’ perspectives, but
standardised scoring for most AEs has yet to be developed.
Hypertension, diabetes, osteoporosis, gastric ulcer, cataract,
glaucoma, infections, and dyslipidaemia are AEs that merit
monitoring. To point out the most important topics for future
research on GCs, a research agenda of 11 research questions has
been formulated through 2 additional Delphi rounds (table 6).
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Table 6 Research agenda developed throughout 2 Delphi rounds
1 What is the perception of patients, general physicians and rheumatologists on efficacy, safety and management of glucocorticoid therapy in rheumatic
diseases? (exploring perceptions and environmental factors as barriers for the effective and safe use of glucocorticoids).
2 What is the influence of low-dose glucocorticoid therapy on lipid profile and other cardiovascular risk factors in relation to active inflammation?
3 What is the pathophysiology of the skin side effects due to the use of glucocorticoids, and how can these be prevented?
4 What is the ideal timing of glucocorticoid treatment regarding safety as well as efficacy?
5 Regarding the use of glucocorticoids in early RA: is a continuous low dose as effective as a step-down dose (starting high and then tapering)?
6 Can we define biomarkers (including genetics) that predict glucocorticoid toxicity?
7 What is the best strategy for prediction, detection and prevention of glucocorticoid-associated cataract and glaucoma?
8 The mechanisms behind individual responsiveness and glucocorticoid resistance should be investigated and the clinical implications clarified.
9 Do glucocorticoids also inhibit radiographic progression in patients with longstanding rheumatoid arthritis?
10 What is the pathophysiological mechanism of steroid myopathy, and can we prevent this; is there a role for specific exercises?
11 Which genomic and non-genomic mechanisms of glucocorticoid actions are responsible for wanted and adverse effects, respectively?
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